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Leading European cardiologists describe the current and planned future
management for acute ST elevation myocardial infarction in their
hospitals and countries in 80 to 100 words.

















Cardiology in Practice in Europe 2011:
Acute ST Elevation Myocardial Infarction
A Snapshot View of the Current Management of Acute
ST Elevation Myocardial Infarction and Future Plans and
Challenges in 25 European Countries
Arevolution in the management of acute ST elevationmyocardial infarction (STEMI) over the past decade
has transformed the emergency and cardiological services
for acute STEMI patients. Underpinning this revolution has
been increasing evidence demonstrating the benefits of pri-
mary percutaneous coronary intervention (PCI) and pre-
PCI and post-PCI management on acute STEMI mortality
and morbidity rates. Within-country and intercountry ini-
tiatives are now in place or in development throughout
Europe to aid this revolution in line with national and
European guidelines.
In this article, leading European cardiologists describe
in 80 to 100 words what has been achieved so far in their
hospitals and countries: the current management for STEMI,
including acute and long-term care, rehabilitation, types of
stents and drugs used, and how these will improve in the
near future. The result is a fascinating glimpse of the work
that has been done and is in progress throughout Europe to
transform the cardiological services and outcome for









Aarhus University Hospital, Skejby, Denmark
“The 4 STEMI centres in Denmark are located in Copen-
hagen, Odense, Aarhus, and Aalborg, and they offer a 24-
hour, 7 days a week primary PCI service for all patients
with acute STEMI. The diagnosis is usually established in
the ambulance to direct the patient straight to the cath lab.
Thrombolysis is not used. Standard medical therapy in the
ambulance is aspirin, a P2Y12 inhibitor, and unfractionated
heparin. Most patients are treated with thrombus aspiration
and direct stenting with a drug-eluting stent and are usually
observed in the STEMI centre for 12 to 48 hours before
transferral to their local hospital for rehabilitation. Patients
are usually included in research projects on new devices and
drugs. Reduction of patient and system delay by public
campaigns and educational programmes is a focus area.”
Finland
(population ≈5.5 million, area ≈338,000km2)
M. J. Pekka Raatikainen, MD, PhD,
FESC, FAHA, professor of cardiology,
Heart Centre Co., Tampere University
Hospital, Tampere, Finland, and
president of the Finnish Cardiac Society
“Primary PCI is the leading reperfusion technique in
Southern Finland. In Tampere University Hospital districts
practically all patients with acute STEMI are treated with
primary PCI. In our centre, the door-to-balloon time is <30
minutes. The operator decides which stent (if any) is most
appropriate for the patient. In the Eastern and Northern
parts of Finland, thrombolysis is used widely because long
travelling distances limit the availability of primary PCI.
The use of long-term medication (aspirin, β-blockers,
statins, etc.) is widespread, and excellent rehabilitation pro-
grammes are available for postmyocardial infarction
patients. The main goals in the near future are to improve
access to primary PCI in the remote areas and to boost the
use of implantable cardioverter-defibrillator and cardiac
resynchronisation therapies in high-risk patients.”
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(population ≈320,000, area ≈103,000km2)
Karl Andersen, MD, PhD, FESC,
professor of cardiology, Landspitalinn,
University Hospital of Iceland,
IS-101 Reykjavik, Iceland
“During the past 25 years, the incidence
and mortality rates of STEMI have dropped by 80% in
Iceland, mostly due to improvements in population risk
factor levels. The University Hospital of Iceland,
Landspitalinn, has a catchment area of 90% of the Icelandic
population and is the only interventional centre in the coun-
try. A 24-hour PCI service was established in 2004.
Currently, 94% of all STEMI patients receiving reperfusion
therapy are treated with acute PCI. More than 95% of all
STEMI patients receive a stent, and ≈30% receive drug-
eluting stents. The median door-to-balloon time is 48 min-
utes, and the 30-day mortality rate after STEMI in Iceland
is 6.5%. The main emphasis in STEMI treatment is to fur-
ther shorten prehospital delays and optimise medical treat-
ment according to international guidelines.”
Ireland
(population ≈4.5 million, area ≈70,000km2)
David P. Foley, MD, PhD, FRCPI, FESC,
FACC, interventional cardiologist,
professor of cardiology, Beaumont
Hospital, Dublin, Republic of Ireland;
chair, Irish Cardiac Intervention Society
“In the Republic of Ireland, primary PCI for STEMI has been
carried out on a variable ad hoc basis for many years. Pene-
tration increased to ≈75% of presenters in urban areas in 2011,
who were treated at 9 centres nationwide. In a typical case,
transradial access has increased dramatically, glycoprotein
IIb/IIIa antagonist use is highly likely, and thrombus aspira-
tion is routine, as is drug eluting stent implantation. Intra-
vascular ultrasound and optical coherence tomography are
used with increasing frequency, depending on the operator. A
strategy of culprit lesion-only PCI is usual, with deferred PCI
for bystander lesions. Patients transported from district hospi-
tals are mostly directly repatriated unless intubated or needing
intra-aortic balloon pump. A national protocol for reperfusion
therapy to provide access to primary PCI for all patients
nationwide starts in October 2011: ≈85% of the population
live within 90 minutes of a PCI centre, and those with STEMI
will be ambulanced directly to the nearest of 4 designated 24/7
PCI centres with full capability. Emergency medical techni-
cians obtain electrocardiograms in the ambulance, and after
confirmation by the receiving cardiology team, administer
aspirin, clopidogrel, and low molecular weight heparin load-
ing doses en route. Patients with STEMI and >2 hours from a
PCI centre receive a thrombolytic locally and are transferred to
the closest PCI centre in case they need rescue PCI. Pros-
pective data collection on all aspects of the programme will be
assessed to ensure optimal outcomes according to internation-
al best practice. Hospital stay is 2 to 3 days for uncomplicated
cases. Cardiac rehabilitation is offered to all patients.”
Latvia
(population ≈2.2 million, area ≈65,000km2)
Andrejs Erglis, FESC, FACC, professor
of cardiology and chief, Latvian
Centre of Cardiology, Pauls Stradins
Clinical University Hospital, Riga,
Latvia, director, Institute of
Cardiology, University of Latvia, and
president of the Latvian Society of Cardiology
“Latvia supports the implementation of the Stent for Life
Initiative (see http://www.stentforlife.com/). According to
the Latvian registry of acute coronary syndromes, the
reperfusion rate for STEMI patients increased from 56% in
2005 to 81% in 2010, mainly due to an increase in primary
PCI from 14% in 2005 to 65% in 2010. Drug-eluting stents
were used in ≈50% of patients. Adherence to dual
antiplatelet therapy, glycoprotein IIb/IIIa inhibitors, low-
molecular-weight heparin, and statins has dramatically
improved. Consequently, the intrahospital mortality rate
has decreased by 34% across the country. The challenges
over the next 10 years are to further increase the use of
drug-eluting stents and total reperfusion rates and to pro-
vide primary PCI for 90% to 100% of STEMI patients.
!orway
(population ≈5 million, area ≈325,000km2)
Karel Kier-Jan Kuiper, MD, PhD,
invasive cardiologist, Department of
Heart Disease, Haukeland University
Hospital, !-5021 Bergen, !orway
“Primary PCI for STEMI is provided
24/7 in 7 regional PCI centres throughout Norway. At our
hospital covering West Norway with an aeromedical serv-
ice, primary PCI is performed for 90% of STEMI patients.
Ambulance-transmitted electrocardiograms are evaluated
for STEMI at the nearest hospital, and dual antiplatelet
therapy is started before transport to a PCI centre. Throm-
bus aspiration and second-generation drug-eluting stents
are increasingly used. For patients with a transfer time >90
to 120 minutes, thrombolysis is administered locally, fol-
lowed by early angiography and ischaemia-driven revascu-
larisation. Care after discharge comprises dual antiplatelet
therapy, statins, β-blocker, and an offer for rehabilitation.
Improvements will focus on reducing ‘time to treatment’ for
patients who have a long transfer time to a PCI centre.”
United Kingdom
(England, population ≈51.5 million,
area ≈130,000km2; Scotland, population
≈5 million, area ≈79,000km2; !orthern
Ireland, population ≈2 million, area
≈14,000km2; Wales, population ≈3 million,
area ≈21,000km2)
KeithA.A. Fox, FRCP, FESC, FMedSci, Duke of Edinburgh
and British Heart Foundation Professor of Cardiology,
University of Edinburgh, Edinburgh, Scotland, and
president of the British Cardiovascular Society
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“The past decade has seen a transformation in the manage-
ment of STEMI in the United Kingdom. From a country
where thrombolytic treatment was the standard of care, the
development of integrated networks of prehospital care for
acute STEMI and the implementation of primary PCI as the
dominant treatment has revolutionised management and out-
comes. Telemetry of the electrocardiogram to the cardiac cen-
tre is increasingly employed, and bypassing of hospitals with-
out primary PCI facilities has expedited treatment. Now, 88%
of patients receive primary PCI within 90 minutes of hospital
presentation, according to the Myocardial Ischaemia National
Audit Project Public Report 2010, and both 30-day and mor-
tality rates for all patients (median age 74 years) fell from
12.35% in 2003 to 8.4% in 2010, with corresponding declines
in 6-month mortality rates. However, there remains scope for
further improvement, including the challenge of late presen-
tation in older and more frail patients.”
Sarah C. Clarke, MD, FRCP, FESC,
FACC, consultant cardiologist and
clinical director for cardiac services,
Papworth Hospital !HS Foundation
Trust, Papworth Everard, Cambridge,
England, and vice president of education
and research for the British
Cardiovascular Society
“The implementation of primary PCI for patients with
STEMI increased access to primary PCI from 27% of the
population in 2008 to 88% by February 2011 in the United
Kingdom. Led by Sir Roger Boyle, National Director for
Heart Disease and Stroke, in collaboration with the Cardiac
Networks, pathways were adapted to different regions.
National and European guidelines are used with regard to
intervention and the use of drug-eluting stents. All patients
are offered cardiac rehabilitation. It is envisaged that pri-
mary PCI will be available to 100% of eligible STEMI
patients by December 2011.”
Western and Eastern Europe
Belgium
(population ≈11 million, area ≈31,000km2)
Peter R. Sinnaeve, MD, PhD, FESC,
professor of cardiovascular medicine,
University Hospitals Leuven – Campus
Gasthuisberg, Leuven, Belgium
“STEMI patients in Belgium are never
remote from expert STEMI care, though a STEMI survey
in 2005 revealed differences in treatment practices and out-
comes between hospitals. A compulsory national STEMI
registry therefore focused on networking. The uptake of
primary PCI as the preferred choice of reperfusion strategy
in non-cathlab centres and corresponding favourable mor-
tality rates illustrate that networking is necessary in a
densely populated country with abundant PCI-capable hos-
pitals. Efforts are now focused on minimising delays at all
levels, as well as on clinical and basic research.”
Czech Republic
(population ≈10.5 million, area ≈79,000km2)
Petr Widimsky, MD, DrSc, FESC,
professor of cardiology, head of the
Cardiocentre, University Hospital
Kralovske Vinohrady, Prague, Czech
Republic, and president of the Czech
Society of Cardiology, 2011 to 2015
“My hospital has used primary PCI for STEMI since 1993.
Thrombolysis was abandoned in our hospital in 1995. The
situation evolved similarly in the entire country over the
next 7 years. Thrombolysis is rarely (<1%) used. Twenty-
two primary PCI centres cover our 10.5 million population,
with each centre performing 200 to 450 primary PCIs for
STEMI each year. STEMI management in the acute phase
includes prehospital electrocardiographic diagnosis and
antithrombotic medication (usually aspirin, clopidogrel,
and heparin) and direct transport to the nearest tertiary primary
PCI centre for emergency coronary angiography followed
by primary PCI. Uncomplicated patients are discharged
after ≈3 to 4 days. Bare metal stents have been used most
often, but this is changing with the introduction of new-
generation drug-eluting stents. Long-term care includes pre-
ventive measures, rehabilitation (outpatient or in specialised
rehabilitation centres), and medication (aspirin, clopido-
grel, β-blockers, statins, angiotensin-converting enzyme
inhibitors). Improvements in the near future will include
the wider use of new-generation drug-eluting stents and the
replacement of clopidogrel by more potent antiplatelet
agents (ie, prasugrel or ticagrelor).”
Germany
(population ≈81 million, area ≈360,000km2)
Thomas Münzel, MD, professor and
chief of cardiology, Johannes Guten-
berg University, Mainz, Germany
“The prognosis for STEMI has consid-
erably improved in Germany over the
past 20 years, primarily due to the network of cath labs
allowing rapid access to primary PCI. We put much
emphasis on decreasing the time delay to reperfusion.
Most delay is caused by the patients themselves, so in
Mainz, we have started awareness campaigns emphasising
what patients with chest pain should do. We also perform a
structured diagnosis, risk stratification, and treatment of all
patients with an acute coronary syndrome in chest pain
units. A network of certified chest pain units is being estab-
lished throughout Germany and so far 130 have been certified
within a couple of years by the German Cardiac Society.”
Hungary
(population ≈10 million, area ≈93,000km2)
Béla Merkely, PhD, DSc, FESC, FACC,
director and chair, Heart Centre,
Semmelweis University, Budapest,
Hungary, and president of the
Hungarian Society of Cardiology
Circulation October 11, 2011 f87
October 11, 2011, pp. f85-f90forpress26.9.11qxp:Cir Euro Template 1  26/09/2011  18:36  Page 3

















Circulation October 11, 2011f88
“Primary care for acute STEMI patients is provided by 17
regional interventional cardiac centres in Hungary. A coun-
trywide network covers the primary cardiac care for almost
the whole area of the ≈10 million citizens. The number of
PCIs for acute coronary syndrome is increasing. In 2010,
>9000 were performed, which is >50% of the total number
of all PCIs. The annual mortality of acute myocardial infarc-
tion decreased from 15,000 in 1993 to 7500 in 2010. Today,
≈66% of hospitalised acute STEMI and non-STEMI
patients are treated with PCI, so Hungary ranks 8th in
Europe for PCI intervention.1 The rate of thrombolytic
therapy for STEMI patients has recently decreased to <1%.”
1. Widimsky P, Wijns W, Fajadet J, de Belder M, Knot J, Aaberge L,
Andrikopoulos G, Baz JA, Betriu A, Claeys M, Danchin N, Djambazov
S, Erne P, Hartikainen J, Huber K, Kala P, Klinceva M, Kristensen SD,
Ludman P, Ferre JM, Merkely B, Milicic D, Morais J, Noc M, Opolski G,
Ostojic M, Radovanovic D, De Servi S, Stenestrand U, Studencan M,
Tubaro M, Vasiljevic Z, Weidinger F, Witkowski A, Zeymer U, European
Association for Percutaneous Cardiovascular Interventions. Reperfusion
therapy for ST elevation acute myocardial infarction in Europe: descrip-
tion of the current situation in 30 countries. Eur Heart J. 2010;31:943–957.
The !etherlands
(population ≈17 million, area ≈34,000km2)
JanJ.Piek,MD,PhD,FESC,FACC,FAHA,
professor of clinical cardiology and dire-
ctor, Heart Centre, Academic Medical
Centre, Amsterdam, the !etherlands
“Completion of the randomised Zwolle
trial almost 20 years ago, showing the superiority of primary
PCI in the treatment of acute myocardial infarction,1 led to a
gradual acceptance in other Dutch regions to use primary PCI
as the first line of treatment. Now almost all patients with acute
myocardial infarction are treated with primary PCI. The well-
equipped ambulance system, short call-to-needle times, and
high-volume centres have contributed to its success, resulting
in a gradual decline in the mortality rate, which is among the
lowest in the world. This achievement has not led to a laidback
attitude, but has rather stimulated Dutch interventionalists to
conduct numerous randomised trials to evaluate adjuvant ther-
apy in primary PCI varying from thrombosuction devices,
glucose metabolism modulation, drug-eluting stents, and
IIb/IIIa receptor blockers to cell therapy. Therefore, if you are
in the unfortunate situation to experience your first acute
myocardial infarction, the Netherlands is a good place to be.”
1. Zijlstra F, de Boer MJ, Hoorntje JC, Reiffers S, Reiber JH, Suryapranata H.
A comparison of immediate coronary angioplasty with intravenous strep-
tokinase in acute myocardial infarction.  Engl J Med. 1993;328:680–684.
Poland
(population ≈38 million, area ≈313,000km2)
Michal Tendera, MD, FESC, FACC,
professor of medicine, Medical Uni-
versity of Silesia, Katowice, Poland
In Poland, as a result of reimbursement
initiatives, >100 catheterisation labs are
open at all times to perform PCI in patients with acute coro-
nary syndrome, so most places in Poland are 50 to 100 km
from a catheterisation lab. Most patients with acute STEMI
therefore receive primary PCI, and thrombolytic treatment of
the STEMI has become virtually obsolete. The number of
cardiologists adequately trained in interventional medicine is,
however, limited, and some patients with STEMI are not
taken to a primary PCI hospital. Now that Europe has become
a limitless travel zone, Poland can also offer primary PCI to
patients living in neighbouring countries close to its primary
PCI centres.
Slovakia
(population ≈5.5 million, area ≈49,000km2)
Martin Studencan, MD, PhD, FESC,
ass. professor of medicine/cardiology,
in charge of Slovak registry of Acute
Coronary Syndromes, Eastern
Slovakia Institute of Cardiovascular
Diseases, Kosice, Slovakia
“Over the past few years, initiatives have been aimed at
educating healthcare professionals and the population.
Changes in clinical practice were analysed using data from
the Slovak Registry of Acute Coronary Syndromes. In
2011, the proportion of patients treated by primary reperfu-
sion increased to 70%, and the proportion of primary PCI-
treated patients could reach 58%. In-hospital mortality rate
decreased from 12.1% in 1998 to 7.45% in 2008. The weak-
est point in Slovakia is an extreme time loss incurred by
patients themselves: the ‘symptoms to electrocardiogram’
interval was 144 minutes in 2008. Educating patients is the
main focus for the next few years.”
Switzerland
(population ≈8 million, area ≈41,000km2)
Dragana Radovanovic, MD, head,
AMIS Plus Data Centre, Institute of
Social and Preventive Medicine, Uni-
versity of Zurich, Zurich, Switzerland
“Since 1997, AMIS (Acute Myocardial
Infarction in Switzerland) Plus has documented the diag-
nostic and therapeutic measures for acute myocardial infarc-
tion, with most hospitals participating. STEMI management is
within the guideline-recommended timeframe (>80%
undergo PCI, >75% within <90 minutes), 25% received
bare metal stents, 70% received drug-eluting stents, ≈90%
received the recommended immediate and discharge drugs,
and ≈54% attended in- or outpatient rehabilitation. Efforts
continue to maintain this high-quality management and to
further shorten delays using prehospital diagnostics and imme-
diate transportation of STEMI patients to a PCI centre.
Southern Europe
Bosnia and Herzegovina
(population ≈4 million, area ≈51,000km2)
Aleksandar M. Lazarevic, MD, PhD,
FESC, associate professor of medicine/
cardiology, University of Banja Luka
Medical School, Banja Luka, Republic
of Srpska, Bosnia and Herzegovina
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“Bosnia and Herzegovina consists of the Republic of
Srpska and the Federation of Bosnia and Herzegovina. The
first and only cath lab in the Republic of Srpska was estab-
lished in June 2007. In 2009, 4% of all patients with
STEMI were treated by primary PCI and 28% of patients
received thrombolytic therapy; ≈68% of patients treated in
hospitals did not receive either thrombolytic therapy or pri-
mary PCI. A major reason for this was late presentation. In
2009, we organised prehospital thrombolytic therapy with
reteplase in 40 emergency departments. In 2010, 9% of
patients were treated by primary PCI. In the Federation of
Bosnia and Herzegovina, 4 hospitals have catheterisation
labs, and 9% of patients were treated by primary PCI.”
Croatia
(population ≈4.3 million, area ≈57,000km2)
Željko Reiner, MD, PhD, FRCP(Lond),
FESC, FACC, professor of internal
medicine and director, University
Hospital Centre Zagreb Salata 2,
10 000 Zagreb, Croatia
“In Croatia, a network was established a number of years ago
based on geographical areas and fast transport to the nearest
hospital. A helicopter service is used for transportation from
the islands and more remote areas, and ambulances, mostly
physician-manned, are used in other parts of the country. In
the hospitals in this network, primary PCI is performed in
STEMI patients. Bare metal stents are usually used rather
than drug eluting stents (≈5% of patients) for financial rea-
sons. Coronary artery bypass grafting is performed if needed.
Aspiration thrombectomy is used routinely in my hospital.
“A relatively high percentage of post-STEMI patients
receive rehabilitation in specialised centres. European
Society of Cardiology guidelines are strictly followed for
drug therapy. Improvements are always possible, particularly
in further development of the organisation, especially to
shorten the door-to-balloon time.
Cyprus
(population ≈803,000, area ≈9,000km2)
Panayiotis Avraamides, FRCP, FESC,
FSCAI, FACC, director, Department of
Cardiology, Limassol General Hospital,
Limassol, Cyprus, and president of the
Cyprus Society of Cardiology and the
Cyprus Working Group on Interventional Cardiology
“More than 90% of acute STEMI patients are treated in the
5 state general hospitals, 2 of which have cath labs. The
rest are treated in private medical centres, 3 of which have
cath labs. The small distances and public awareness of the
symptoms of myocardial infarction translate into rapid
therapy. When the cath labs are open, patients are treated
by primary PCI, but at nights and on weekends and in hos-
pitals without invasive facilities, thrombolysis is the main-
stay of treatment. The low rates of primary PCI are due to
a lack of trained interventionalists. We are addressing this
with intensive training programmes to provide enough
trained personnel for a 24-hour 7 days a week primary PCI
programme by 2012. Whether this happens, however,
depends on whether the government will provide funding
in this time of public cost cutting.
“Stents are used in almost 100% of primary PCIs. Until
recently, mainly due to concerns about thrombosis with
drug-eluting stents, the majority were bare metal stents.
This has changed, and >80% of stents for primary PCI are
now drug-eluting stents. All guideline drugs are in use with
a few exceptions: clopidogrel is the thienopyridine in gen-
eral use, and although prasugrel is available, it is not in use
in the state hospitals due to its cost. Bivalirudin is not widely
available. All patients are followed up by a cardiologist
with guideline-based management in both state and private
centres: 80% of the population is eligible for free healthcare.
“No large-scale official rehabilitation programmes have
been available. We are addressing this, partly by the estab-
lishment this year of a new working group on cardiac reha-
bilitation to study this issue and make recommendations.”
Greece
(population ≈11.5 million, area ≈132,000km2)
Gerasimos Filippatos, MD, FACC,
FCCP, FESC, chief of the Heart
Failure Unit, Department of
Cardiology, Athens University
Hospital, Athens, Greece
“In Greece, with thousands of islands and only 10 primary
PCI centres, the reperfusion rates for STEMI in 2005 were
≈65%. Of the patients admitted to hospitals with a cath lab,
24% had primary PCI in comparison with 1% of patients
admitted to small peripheral hospitals. An unexpected find-
ing is the relative underuse of common treatments in the
peripheral hospitals. Initiation of STEMI networks in most
regions, coordinated centrally by Professor John Nanas,
has improved reperfusion rates and the use of primary PCI
and evidence-based therapies.”
Israel
(population ≈8 million, area ≈21,000km2)
Morris Mosseri, MD, head of the
Cardiovascular Division, Meir Medical
Centre, Kfar-Sava, Israel
“At Meir Medical Centre, all patients with
STEMI undergo primary PCI. Data on
treatment of STEMI in Israel is provided by the 10th Israeli
Biennial National Survey on Acute Coronary Syndromes of
776 patients performed in 26 hospitals between March and
April 2010. Median door-to-balloon time was 68 minutes.
Reperfusion was by primary PCI in 94%, thrombolysis in
4%, and urgent coronary artery bypass grafting in 1%. During
primary PCI, ≈57% of patients were treated with IIb-IIIa
antagonists, ≈6% with bivalirudin, and ≈46% with an aspira-
tion/protective device. Stents were implanted in 90% of
patients (bare metal 78%, drug-eluting 18%, both types 3.4%).
Medical treatment on discharge usually includes aspirin,
clopidogrel, statin, β-blocker, and angiotensin-converting
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enzyme inhibitor or angiotensin receptor blocker. The 30-day
mortality and major adverse cardiovascular event rates were
4.1% and 10.4%, respectively. At Meir Medical Centre, 40%
of patients have rehabilitation. The rate is 0% to 50% for
other centres. The Israel Heart Society is planning a campaign
to shorten the time from symptom onset to seeking help.”
Italy
(population ≈61 million, area ≈301,000km2)
Raffaele De Caterina, MD, PhD,
professor of cardiology and director
of the Institute of Cardiology,
“G. d’Annunzio” University,
Chieti-Pescara, Chieti, Italy
“Acute STEMI is treated by primary PCI almost by default
in my hospital and in my city (Chieti), but some areas in the
province are too remote for quick transportation to our ter-
tiary care hospital. For this reason, I feel it is important that
the ‘culture of thrombolysis’ is not lost. In training young
cardiologists, I insist that they have knowledge about the
management of STEMI with tenecteplase and know how to
recognise failed reperfusion that needs rescue treatment in
these patients.”
(Republic of) Macedonia
(population ≈2 million, area ≈26,000km2)
Borce Petrovski, MD, PhD, FESC,
FACC, interventional cardiologist and
director, Institute for Heart Diseases,
Clinical Centre, University of St. Ciril
and Metodius, Skopje, Macedonia
“Macedonia provides full government health insurance to
its population of 2 million and 3 PCI centres. The furthest
distance to a PCI centre is <2 hours in an ambulance. Primary
PCI was started in 1995. In 2003, a national strategy for
acute STEMI treatment was established. Reperfusion is
carried out in 91% of patients: primary PCI in 71.5% and
thrombolytic therapy in 19.5%. A printed algorithm in
accordance with European Society of Cardiology treatment
guidelines is distributed in every medical institution. Door-
to-balloon time is 46 minutes. Primary PCI is performed for
cardiogenic shock, severe coronary heart disease, haemo-
dynamic/electrical instability, persistent ischemia, and failed
thrombolytic therapy. Early physical activity and secondary
prevention are also recommended in the national strategy.
Serbia
(population ≈7 million, area ≈88,000km2)
Miodrag Ostojic, MD, PhD, FACC,
FESC, FSCAI, professor of cardiology,
Division of Cardiology, Medical
School of Belgrade, Belgrade, Serbia
“Serbia is 1 of 10 countries that has far
from optimal reperfusion strategies for STEMI and is
included with prospective follow-up in the Stent for Life
Initiative (see http://www.stentforlife.com/). Impressive
improvements were registered in 2009, with 34.2% and
28.3% of patients treated by primary PCI and hospital
thrombolysis, respectively, in 9 centres. Further progress in
2010 and 2011 has been observed. Two new centres are
about to open in central and southeast Serbia. The focus is
now on improving the prehospital administration of aspirin
and clopidogrel and avoiding delays in transferring patients
to the cath lab.”
Slovenia
(population ≈2 million, area ≈20,000km2)
Marko !oc, MD, PhD, FESC,
professor of medicine, Medical School
Ljubljana, and head of the Centre for
Intensive Medicine, University
Medical Centre, Ljubljana, Slovenia
“Slovenia is well covered by highways and emergency
helicopter transport. Primary PCI has been the only reper-
fusion method for STEMI for several years. Of 5 interven-
tional centres, 2 provide a 24/7 service and treat the major-
ity of STEMI patients (650 and 450 primary PCIs per year,
respectively). A ‘fast track’ with direct transfer from the
field or from a non-PCI hospital to the cath lab reduces
time delays to reperfusion. Most patients are pretreated
with aspirin, thienopyridine, and heparin. Manual aspira-
tion and bare metal stents are usually used. Improving links
for the fast track, reducing the proportion of late presenters,
and optimising treatment of survivors of prehospital car-
diac arrest are ongoing challenges.”
Tunisia
(population ≈10.5 million, area ≈164,000km2)
Habib Haouala, MD, FESC, professor
of cardiology, University of Tunis, Tunis,
Tunisia, head, Cardiology Department,
Principal Military Hospital Tunis, and
past-president Tunisian Society of
Cardiology and Cardiovascular Surgery
“Only 15% of acute STEMI patients are taken by ambu-
lance to the emergency room. Mechanical or pharmacolog-
ical reperfusion is performed for 40% of patients present-
ing within 12 hours. Antithrombin and antiplatelet agents
are widely used, except bivalirudin and fondaparinux,
which are not available. Rehabilitation is underused
because of the lack of centres. Programmes to improve the
quality of care for acute STEMI include improving the
emergency ambulance and medical services, establishing a
national registry on STEMI management, creating a net-
work between different PCI departments, and increasing
the number of cardiac rehabilitation centres.”
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